Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free AGY Stock Alerts

Allergy Therapeutics (AGY) Competitors

Allergy Therapeutics logo
GBX 5.10 -0.15 (-2.86%)
As of 08/21/2026 12:44 PM Eastern
Compare

AGY vs. VEC, ERGO, BMY, AMYT, and APH

Should you buy Allergy Therapeutics stock or one of its competitors? Allergy Therapeutics's main competitors and comparable companies include Vectura Group (VEC), Ergomed (ERGO), Bloomsbury Publishing (BMY), Amryt Pharma (AMYT), and Alliance Pharma (APH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Allergy Therapeutics compare to Vectura Group?

Vectura Group (LON:VEC) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Vectura Group has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Vectura Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vectura Group£190.60M0.00N/A£20.10N/A
Allergy Therapeutics£57.29M5.64-£52.59M-£0.97N/A

0.0% of Allergy Therapeutics shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vectura Group has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Vectura Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Vectura GroupN/A N/A N/A
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Allergy Therapeutics had 1 more articles in the media than Vectura Group. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Vectura Group. Vectura Group's average media sentiment score of 0.00 equaled Allergy Therapeutics'average media sentiment score.

Company Overall Sentiment
Vectura Group Neutral
Allergy Therapeutics Neutral

Summary

Vectura Group beats Allergy Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Allergy Therapeutics compare to Ergomed?

Allergy Therapeutics (LON:AGY) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Ergomed has a net margin of 9.87% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Ergomed's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Ergomed 9.87%18.08%10.16%

In the previous week, Allergy Therapeutics had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Ergomed. Allergy Therapeutics' average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Ergomed Neutral

Ergomed has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.64-£52.59M-£0.97N/A
Ergomed£152.09M0.00£15M£0.29N/A

Allergy Therapeutics has a beta of 0.835, indicating that its share price is 17% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

0.0% of Allergy Therapeutics shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 3.6% of Allergy Therapeutics shares are held by company insiders. Comparatively, 18.2% of Ergomed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ergomed beats Allergy Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Allergy Therapeutics compare to Bloomsbury Publishing?

Bloomsbury Publishing (LON:BMY) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends.

Bloomsbury Publishing has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Bloomsbury Publishing, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bloomsbury Publishing£325.90M1.62£37.37M£32.8019.94
Allergy Therapeutics£57.29M5.64-£52.59M-£0.97N/A

Bloomsbury Publishing presently has a consensus price target of GBX 800, suggesting a potential upside of 22.32%. Given Bloomsbury Publishing's stronger consensus rating and higher probable upside, equities research analysts clearly believe Bloomsbury Publishing is more favorable than Allergy Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bloomsbury Publishing
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Allergy Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Bloomsbury Publishing has a net margin of 8.28% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Bloomsbury Publishing's return on equity.

Company Net Margins Return on Equity Return on Assets
Bloomsbury Publishing8.28% 12.74% 7.82%
Allergy Therapeutics -85.46%409.00%-34.76%

In the previous week, Bloomsbury Publishing and Bloomsbury Publishing both had 1 articles in the media. Bloomsbury Publishing's average media sentiment score of 0.75 beat Allergy Therapeutics' score of 0.00 indicating that Bloomsbury Publishing is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bloomsbury Publishing
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allergy Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bloomsbury Publishing has a beta of 0.418, suggesting that its share price is 58% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, suggesting that its share price is 17% less volatile than the broader market.

42.2% of Bloomsbury Publishing shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 3.6% of Bloomsbury Publishing shares are held by company insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Bloomsbury Publishing beats Allergy Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Allergy Therapeutics compare to Amryt Pharma?

Allergy Therapeutics (LON:AGY) and Amryt Pharma (LON:AMYT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Amryt Pharma has a net margin of 0.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Amryt Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Amryt Pharma N/A N/A N/A

In the previous week, Allergy Therapeutics had 1 more articles in the media than Amryt Pharma. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Amryt Pharma. Allergy Therapeutics' average media sentiment score of 0.00 equaled Amryt Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Amryt Pharma Neutral

Amryt Pharma has higher revenue and earnings than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.64-£52.59M-£0.97N/A
Amryt Pharma£210.24M0.00N/A-£33.00N/A

0.0% of Allergy Therapeutics shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Allergy Therapeutics beats Amryt Pharma on 5 of the 9 factors compared between the two stocks.

How does Allergy Therapeutics compare to Alliance Pharma?

Allergy Therapeutics (LON:AGY) and Alliance Pharma (LON:APH) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Alliance Pharma has higher revenue and earnings than Allergy Therapeutics. Alliance Pharma is trading at a lower price-to-earnings ratio than Allergy Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allergy Therapeutics£57.29M5.64-£52.59M-£0.97N/A
Alliance Pharma£183.50M1.91-£33.65M-£6.20N/A

0.0% of Allergy Therapeutics shares are owned by institutional investors. Comparatively, 66.3% of Alliance Pharma shares are owned by institutional investors. 3.6% of Allergy Therapeutics shares are owned by insiders. Comparatively, 12.0% of Alliance Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alliance Pharma has a net margin of -6.00% compared to Allergy Therapeutics' net margin of -85.46%. Allergy Therapeutics' return on equity of 409.00% beat Alliance Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Allergy Therapeutics-85.46% 409.00% -34.76%
Alliance Pharma -6.00%-5.04%5.98%

In the previous week, Allergy Therapeutics had 1 more articles in the media than Alliance Pharma. MarketBeat recorded 1 mentions for Allergy Therapeutics and 0 mentions for Alliance Pharma. Allergy Therapeutics' average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company Overall Sentiment
Allergy Therapeutics Neutral
Alliance Pharma Neutral

Allergy Therapeutics has a beta of 0.835, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Alliance Pharma has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Summary

Allergy Therapeutics and Alliance Pharma tied by winning 6 of the 12 factors compared between the two stocks.

Get Allergy Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGY vs. The Competition

Export
MetricAllergy TherapeuticsPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£322.96M£12.57B£7.37B£2.54B
Dividend Yield8.33%2.61%2.53%6.17%
P/E Ratio-5.26789.80272.60367.57
Price / Sales5.64764.53624.3383,481.74
Price / Cash3.6696.7778.6227.89
Price / Book51.6811.8913.057.19
Net Income-£52.59M£2.81B£3.47B£5.89B
7 Day Performance-5.90%1.77%2.09%0.30%
1 Month Performance-13.56%3.85%6.64%3.31%
1 Year Performance-41.38%6.56%25.02%22.13%

Allergy Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGY
Allergy Therapeutics
N/AGBX 5.10
-2.9%		N/A-41.4%£322.96M£57.29MN/A612
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386
BMY
Bloomsbury Publishing
3.6391 of 5 stars		GBX 649
-0.3%		GBX 800
+23.3%		+32.0%£524.67M£325.90M19.7934,300
AMYT
Amryt Pharma
N/AN/AN/AN/A£457.11M£210.24MN/A290

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:AGY) was last updated on 8/23/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel